How seizures fuel cognitive decline and addiction risk

Epilepsy is a complex neurological disorder that includes recurrent seizures and significant cognitive impairment, which substantially contribute to disease burden. This review presents an integrated mechanistic and clinical framework linking epilepsy, cognition, and addiction, emphasizing their shared and interacting neurobiological pathways. Recurrent seizure activity induces chronic neuroinflammation, oxidative stress, and mitochondrial dysfunction, leading to disrupted synaptic plasticity and neurotransmitter imbalance, particularly within glutamatergic and dopaminergic systems. These alterations underlie deficits in memory, attention, and executive function. Concurrently, dysfunction of mesocorticolimbic reward circuitry increases susceptibility to substance use disorders, including alcohol, nicotine, opioid, and cannabis dependence. Substance use further destabilizes neuronal excitability, alters antiseizure drug pharmacokinetics, and accelerates cognitive decline, establishing a bidirectional and self-reinforcing cycle. Epigenetic modifications and maladaptive neuroplasticity further sustain this interaction. Clinically, the coexistence of epilepsy, cognitive impairment, and substance use presents major challenges, including diagnostic complexity, poor treatment adherence, polypharmacy, increased hospitalization, reduced functional independence, and elevated risk of mortality, including sudden unexpected death in epilepsy. These challenges highlight the limitations of seizure-focused care and the need for comprehensive management strategies. Moreover, therapeutic approaches should integrate cognitive rehabilitation, behavioral and psychological interventions, dietary therapies, neuromodulation techniques, and rational pharmacological optimization, alongside structured addiction management and supportive lifestyle measures. Multidisciplinary care models combining neurology, psychiatry, neuropsychology, and addiction medicine are essential for improving outcomes. Additionally, future directions should prioritize biomarker-driven precision medicine, longitudinal and standardized cognitive assessment, development of dual-targeted interventions, neuroprotective and anti-inflammatory therapies, and the use of digital health technologies for monitoring and intervention. Early identification and integrated care remain critical to preventing long-term cognitive decline and addiction-related complications.